| Developmental outcome in very low birthweight infants. Current status and future trends. | |
| | |
MedLine Citation:
|
PMID: 9653444 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Surfactant therapy has significantly reduced mortality, but not morbidity, in the very low birthweight (VLBW) infant. Questions persist as to the edge of viability, the allocation of health care resources for the VLBW infant, and whether or not we are improving survival at the cost of contributing more handicapped individuals to society. Since surfactant alone has not reduced morbidity, other medical and behavioral treatments are being studied that may help to optimize neurodevelopmental outcome in the VLBW infant. |
| | |
Authors:
|
J Bregman |
Related Documents
:
|
16021414 - Sibling birthweight as a predictor of macrosomia in women with type 1 diabetes. 15832544 - Neurobehavioural profile of low-birthweight infants with cystic periventricular leukoma... 12108064 - Two key strategies in the nutritional management of the extremely low birth weight infant. 15512064 - Perinatal factors influencing survival in extremely low-birthweight infants. 3509974 - Neonatal morphometrics and perinatal outcome: who is growth retarded? 2797944 - Zinc and copper nutritional studies in very low birth weight infants: comparison of sta... |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Pediatric clinics of North America Volume: 45 ISSN: 0031-3955 ISO Abbreviation: Pediatr. Clin. North Am. Publication Date: 1998 Jun |
Date Detail:
|
Created Date: 1998-07-16 Completed Date: 1998-07-16 Revised Date: 2004-11-17 |
Medline Journal Info:
|
Nlm Unique ID: 0401126 Medline TA: Pediatr Clin North Am Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: 673-90 Citation Subset: AIM; IM |
Affiliation:
|
Department of Pediatrics, Evanston Northwestern Healthcare, Evanston Hospital, Illinois, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Child Cost-Benefit Analysis Developmental Disabilities / etiology*, prevention & control Humans Infant, Newborn Infant, Very Low Birth Weight* Morbidity Pulmonary Surfactants / economics, therapeutic use* Respiratory Distress Syndrome, Newborn / complications, drug therapy*, mortality Survival Analysis Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Pulmonary Surfactants |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Principles of disease management in neonatology.
Next Document: The death of a baby in the infant special care unit.